DCT

1:25-cv-01532

Pfizer Inc v. Apotex Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:25-cv-01532, D. Del., 12/18/2025
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant Apotex Corp. is a Delaware corporation, and Defendant Apotex Inc. is alleged to have purposefully availed itself of the jurisdiction through its and its subsidiary's business activities in the state.
  • Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) for a generic version of the drug Vyndamax® (tafamidis) constitutes infringement of a patent claiming a specific crystalline form of the active pharmaceutical ingredient.
  • Technical Context: The technology relates to pharmaceutical polymorphs-distinct crystalline structures of the same chemical compound-which can have different physical properties affecting a drug's stability, manufacturability, and performance.
  • Key Procedural History: The complaint notes a complex procedural background involving two separate notice letters from Apotex. An initial notice on September 9, 2025, led to a lawsuit by Pfizer on October 24, 2025. Subsequently, Apotex allegedly informed Pfizer that its Paragraph IV certification was not maintained, but then re-filed it and sent a second notice letter on November 5, 2025. This action is filed in response to the second notice.

Case Timeline

Date Event
2014-09-08 '441 Patent Priority Date
2017-09-26 U.S. Patent No. 9,770,441 Issue Date
2025-09-09 Apotex sends First Notice Letter of ANDA filing
2025-10-24 Plaintiffs file initial complaint against Apotex
2025-11-05 Apotex sends Second Notice Letter of ANDA filing
2025-12-18 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,770,441 - "CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-(3,5-DICHLOROPHENYL)-BENZOXAZOLE"

The Invention Explained

  • Problem Addressed: The patent background explains that while the compound 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole (the active ingredient tafamidis) is known to treat transthyretin amyloid diseases by stabilizing the TTR protein, there is a need to identify and characterize specific solid forms of the compound for pharmaceutical development Compl. ¶26 '441 Patent, col. 1:33-47 The development of suitable dosage forms requires a consistent, stable solid form, as different forms can have varying properties like solubility, stability, and bioavailability, which are critical for safety and efficacy '441 Patent, col. 1:48-64
  • The Patented Solution: The invention provides specific crystalline solid forms of tafamidis, identified and defined by their unique analytical characteristics. The patent describes several polymorphs, with the claims directed to forms identified by specific peaks in powder X-ray diffraction (PXRD) patterns, solid-state Nuclear Magnetic Resonance (NMR) spectra, and Raman spectra '441 Patent, abstract '441 Patent, col. 2:6-14 Claim 1, for instance, claims what the specification refers to as "Form 1," defined by a choice of such analytical parameters '441 Patent, col. 2:16-24
  • Technical Importance: Controlling the polymorphic form of an active pharmaceutical ingredient is crucial in drug manufacturing to ensure batch-to-batch consistency, predictable dissolution rates, and overall product quality and therapeutic effect '441 Patent, col. 10:5-15

Key Claims at a Glance

  • The complaint asserts infringement of one or more of claims 1-16, with a focus on independent claim 1 and exemplary claims 15 (composition) and 16 (method of use) Compl. ¶45 Compl. ¶46 Compl. ¶49 Compl. ¶51
  • Independent Claim 1 consists of the following essential elements:
    • A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole.
    • Wherein the crystalline form has an analytical parameter from a Markush group consisting of:
      • a solid state NMR spectrum with 13C chemical shifts at 120.8±0.2 and 127.7±0.2 ppm, OR
      • a powder X-ray diffraction pattern with a peak at a diffraction angle (2θ) of 28.6±0.2, OR
      • a Raman spectrum with a Raman shift peak at 1292±2 cm-1.
  • The complaint alleges infringement of claims 1-16 and reserves the right to assert other claims from the '441 Patent Compl. ¶45 Compl. ¶55

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Apotex's generic tafamidis 61 mg capsules, for which Apotex submitted ANDA No. 218905 to the FDA for approval Compl. ¶1 Compl. ¶2

Functionality and Market Context

The product is a generic version of Plaintiffs' Vyndamax® drug, intended for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis Compl. ¶26 Compl. ¶28 The complaint alleges that the filing of the ANDA, which seeks approval to market this generic product prior to the expiration of the '441 Patent, is an act of infringement Compl. ¶1 Compl. ¶53 The key technical feature relevant to the infringement allegation is the specific crystalline form of the tafamidis active ingredient contained within the proposed generic product Compl. ¶48 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

'441 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole, Apotex's ANDA Product contains tafamidis, which is the chemical compound 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole. ¶47 col. 1:19-32
wherein said crystalline form has an analytical parameter selected from the group consisting of a solid state NMR spectrum comprising 13C chemical shifts (ppm) at 120.8±0.2 and 127.7±0.2, a powder X-ray diffraction pattern comprising a peak at a diffraction angle (2θ) of 28.6±0.2, and a Raman spectrum comprising a Raman shift peak (cm¯¹) at 1292±2. On information and belief, Apotex's ANDA product contains a crystalline form of tafamidis that has a solid state NMR spectrum, a powder X-ray diffraction pattern, or a Raman spectrum matching the parameters recited in the claim. ¶48 col. 23:6-18
  • Identified Points of Contention:
    • Evidentiary Question: The primary dispute will likely be factual and evidentiary. The complaint alleges, on information and belief, that Apotex's product will meet the analytical criteria of claim 1. This raises the question: what analytical data from Apotex's ANDA and product samples will show? The case may turn on whether Apotex's product can be proven to possess the specific crystalline structure claimed, or if it utilizes a different, non-infringing polymorph, an amorphous form, or if the data is ambiguous.
    • Scope Question: Claim 1 is a Markush claim, meaning infringement can be found if the accused product meets just one of the three alternative analytical prongs (NMR, PXRD, or Raman). A potential point of contention is whether the accused product, while perhaps avoiding one or two of the prongs, can be shown to fall within the specified parameters of the third.

V. Key Claim Terms for Construction

  • The Term: "crystalline form"

  • Context and Importance: The distinction between a specific "crystalline form," other crystalline forms (polymorphs), and the "amorphous" form is central to the patent's scope. The definition of this term will be critical for determining whether Apotex's product, if it contains any crystalline material, falls within the scope of the claims.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification provides a general definition: "any solid substance exhibiting three-dimensional order, which in contrast to an amorphous solid substance, gives a distinctive PXRD pattern with sharply defined peaks" '441 Patent, col. 12:1-5
    • Evidence for a Narrower Interpretation: A party might argue that the term, in the context of the claims, is implicitly limited to the specific polymorphs detailed (e.g., "Form 1"), as produced by the methods described in the patent's examples '441 Patent, col. 21:54-65

  • The Term: "a peak at a diffraction angle (2θ) of 28.6±0.2" (and similar terms with "±" tolerances)

  • Context and Importance: The definition of the "±" tolerance is critical for determining the literal boundary of the claim. Whether a peak that falls near, but just outside, the numerical range infringes will depend on how this tolerance is construed.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification explicitly acknowledges measurement variability, stating that PXRD peak positions can vary by "as much as 0.1 to 0.2 degrees" depending on the apparatus and other factors '441 Patent, col. 11:36-44 A party could argue the "±" notation should be interpreted flexibly in light of this inherent instrumental variance.
    • Evidence for a Narrower Interpretation: A party could argue that the explicit inclusion of "±0.2" represents a deliberate choice by the patentee to define a precise boundary that already incorporates expected experimental error, and that any peak outside this range is definitively non-infringing.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement, stating that the proposed labeling for Apotex's ANDA Product directs and encourages a method of treatment that infringes claim 16 of the '441 patent Compl. ¶52 Compl. ¶57 Contributory infringement is also alleged, on the basis that the product is especially made for an infringing use and is not a staple article of commerce Compl. ¶58
  • Willful Infringement: The complaint alleges that Apotex acted with full knowledge of the '441 patent, established by the notice letters, and without a reasonable basis for believing it would not be liable, thereby supporting a claim for willful infringement Compl. ¶61

VII. Analyst's Conclusion: Key Questions for the Case

  1. A central issue will be one of evidentiary proof: Will discovery and expert analysis of Apotex's ANDA product demonstrate that it contains a crystalline form of tafamidis that exhibits at least one of the specific analytical fingerprints (NMR, PXRD, or Raman) required by Claim 1?

  2. A second key question will involve validity: As part of its defense, Apotex has certified that the '441 Patent is invalid Compl. ¶44 The case will therefore likely address whether the claimed "Form 1" polymorph is novel and non-obvious over prior art related to tafamidis, or whether it was an inherent or obvious consequence of prior methods for making or purifying the compound.

  3. Finally, a question of claim construction may arise regarding the scope of the claimed analytical parameters. The court may need to determine the precise boundaries of terms like "28.6±0.2," and how to account for experimental variability in analytical chemistry when comparing the accused product to the claim limitations.

Loading Complaint